FIELD: medicine; pharmacology.
SUBSTANCE: invention refers to medicinal agents and concerns pharmaceutical formulation for nasal absorption containing biologically active acidic polypeptide with isoelectric point 7 and lower; carrier which is water-insoluble or weak-soluble and contains particles of average size 100 mcm and less; and adjuvant for dispersion and consolidation of polypeptide on carrier surface, which is water-insoluble or weak-soluble, where average size of particle contained in specified adjuvant is lower than average size of carrier and is within the range 1 mcm to 20 mcm.
EFFECT: improved biological acceptability of biologically active polypeptide.
6 cl, 4 dwg, 11 tbl, 47 ex
| Title | Year | Author | Number |
|---|---|---|---|
| STABLE NON-AQUEOUS PHARMACEUTICAL COMPOSITIONS | 2008 |
|
RU2472492C2 |
| PHARMACEUTICAL COMPOSITIONS OF hGLP-1, EXENDIN-4 AND THEIR ANALOGUES | 2007 |
|
RU2419452C2 |
| PHARMACEUTICAL COMPOSITIONS GLP-1 | 2007 |
|
RU2445972C2 |
| IONIC MOLECULAR CONJUGATES OF BIODEGRADABLE COMPLEX POLYESTERS AND BIOACTIVE POLYPEPTIDES | 2000 |
|
RU2237681C2 |
| NOVEL ANALOGUES OF GLUCAGON-LIKE PEPTIDE, COMPOSITION AND METHOD OF USE | 2010 |
|
RU2557301C2 |
| STABILISED COMPOUNDS OF EXENDIN-4 | 2003 |
|
RU2376314C2 |
| POLYPEPTIDES SELECTIVE TO GLUCAGON RECEPTORS AND THEIR APPLICATION METHODS | 2017 |
|
RU2760007C2 |
| GLP-1 PEPTIDES COMPOSITIONS AND THEIR PRODUCTION | 2013 |
|
RU2641198C2 |
| GLP-I-MOLECULAR COMPLEX, PHARMACEUTICAL COMPOSITION AND METHOD OF COMPLEX PREPARING | 1995 |
|
RU2147588C1 |
| PEPTIDE COMPOSITION CONTAINING PROPYLENE GLYCOL OPTIMAL FOR MANUFACTURING AND APPLICATION IN INJECTION DEVICES | 2004 |
|
RU2421238C2 |
